Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs AT&T Inc. (T) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs AT&T Inc. — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while AT&T Inc. trades at $24.48 (market cap $164.80B). The key difference: AT&T Inc. is far larger — about 2599× Heron Therapeutics Inc's market cap, and AT&T Inc. pays a 4.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXT
Market Cap
$63.41M$164.80B
Sector
HealthMedia
52-Week High
$1.49$29.62
52-Week Low
$0.33$20.49
Enterprise Value
$161.31M$310.12B
Dividend Yield
4.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

AT&T Inc.

AT&T (T) trades at $23.80, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.65 exceeding the $0.59 estimate. Revenue grew to $125.65 billion in 2025, and net income surged to $21.95 billion, reflecting a robust profit margin of 17.47%. Recent news highlights fiber expansion and 5G network investments.

The outlook is positive, supported by improving cash flow, strategic investments, and a 4.8% dividend yield. However, risks include competitive pressure from new entrants like SpaceX's Starlink and high debt levels. Analyst sentiment is mixed but leans bullish, with 41% buy ratings. The stock presents a value opportunity with a low P/E of 7.85, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.

Read more on T